Worldwide, MLD occurs in 1 in 40,000 people, primarily children. Early symptoms of MLD include trouble walking, impaired speech, and muscle weakness.
The Embolden Study is conducting research for infants and children born with metachromatic leukodystrophy.
Study overview:
The Embolden Study is evaluating the safety and effects of a study drug on gross motor function (the abilities required to control the large muscles of the body for walking, running, sitting, crawling, and other activities) in children with late infantile MLD. This clinical research study has the potential to impact families in the future, and your child’s participation may contribute to bringing forth a treatment option for other children diagnosed with MLD.
If your child has been diagnosed with metachromatic leukodystrophy, the Embolden Study may be an option. Learn more about this MLD study at http://bit.ly/2IhDe59.
